Clinical performance and treatment of systemic cardiovascular disease
Clinical performance
All-body symptoms.
The majority of patients have a whole body of non-specific manifestations of fever, inactivity and weight loss. Heat levels vary, can be low or high, and duration varies.
Skin performance
It is common to have rashes, which can be shown in the form of purple plasters, red spots, rubles, mesh and so on. The most typical is the rash, which is distributed more in the lower limbs, which is higher than the skin surface and is not diluted. Skin ulcer is also likely to occur, especially in patients with higher or longer conditions, where ulcer can be prolonged and accompanied by pain.
Symptoms of joint muscles
There are several joints that can be exhausted, as shown by the pain and swelling of the joint, and some patients are restricted in their activities. The degree of pain varies considerably, ranging from mild to severe pain, and is relatively common with large joints. Muscle stress can result in muscle incapacitation and muscle pain, which seriously affects the patient ‘ s mobility.
Kidney’s tired.
Symptoms such as protein urine, blood urine and oedema can develop into kidney failure. The level of kidney damage varies, with a greater impact on the patient ‘ s prognosis, and some patients may need long-term dialysis treatment.
Cardiovascular system performance
It causes narrow or extended blood vessels, high blood pressure, heart infarction, heart disorder, etc. Patients may have symptoms such as chest pain, heart palpitation, respiratory difficulties, and serious cardiovascular complications can endanger life.
Indigestion system performance
Abdominal pain and diarrhoea are common, and serious cases of digestive haemorrhage and intestine infarction can occur. Patients can manifest themselves differently depending on the nature and degree of abdominal pain, ranging from mild abdominal discomfort to severe pain.
Medical care
Diagnosis
It is based on a combination of clinical performance, laboratory and video-testing. In laboratory tests, blood sunk and C-reacting proteins increased, reflecting inflammation activity. Some patients may have anti-neutral particle cell plasma antibodies (ANCA) positive, which is important for diagnosis. Visual examinations include angiography, CT, MRI, etc., which can show angiogenesis, such as vascular narrowness, expansion, thickening of tube walls, etc. Organizational biopsy is essential for a clear diagnosis, and pathological changes such as inflammation of inflammation cells in the vascular wall and the death of cellulose are observed through a pathological examination of tired tissues (e.g. skin, kidney, etc.).
Treatment
1. Sugar cortex hormones: a primary drug of treatment that reduces the inflammatory response and the symptoms. The use of the dose depends on the severity of the condition, which requires a gradual reduction after the condition is controlled.
Immunosuppressants: Often used in conjunction with sugary cortex hormones, such as cyclophosphate, sulfur, etc., can better control the condition and reduce relapse.
3. Biological agents: A certain level of healing for incurable vascular disease, which can target cytogens or cellular pathways associated with inflammation. In the course of treatment, there is a need to monitor closely the adverse effects of drugs, to assess the situation regularly and to adjust treatment programmes.
